| |
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
Today’s Big NewsJul 16, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Conor Hale Masimo has asked a federal court to intervene in its ongoing proxy fight with Politan Capital Management, with a lawsuit that seeks to force the activist investor to “correct material misstatements and omissions” in its materials sent to shareholders. |
|
|
|
By Zoey Becker The Swedish drugmaker reported 13% sales growth in its hematology portfolio, which includes brands such as Doptelet, Vonjo and Apellis-partnered Empaveli (or Aspaveli in Europe, which is one of Sobi's territories). |
By James Waldron As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel. |
By Darren Incorvaia Vertex struck gold with the licensing of CRISPR Therapeutics’ sickle cell gene editing therapy in 2017. With that med now approved as Casgevy, Vertex is looking to extend its claim in gene editing therapy through a small licensing deal with South Korea's Orum. |
|
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now. 
|
|
By Kevin Dunleavy ICER has issued "an access and affordability alert" for Verona Pharma’s newly approved Ohtuvayre (ensifentrine), a long-awaited treatment for chronic obstructive pulmonary disease (COPD). ICER has calculated Ohtuvayre's cost-effective price range to fall between $7,500 and $12,700 annually, while Verona is charging $34,500 annually for the first-in-class treatment. |
By Conor Hale The company’s software received an FDA clearance in June 2023, which allowed it to connect with a range of regulated tools. |
By Nick Paul Taylor Sionna Therapeutics has quickly found a use for some of its $182 million series C haul, inking a deal with AbbVie to add three clinical-phase candidates to its burgeoning pipeline of cystic fibrosis prospects. |
By Kevin Dunleavy Vertex has filed a lawsuit in federal court in Washington, D.C. against the U.S. Department of Health and Human Services (HHS) seeking to overturn the “erroneous legal positions” of the agency’s Office of the Inspector General (OIG). Vertex wants to provide a fertility preservation assistance program for patients using its gene therapy for sickle cell disease and beta thalassemia. |
By Nick Paul Taylor Lawmakers are mounting yet another attempt to change the rules on taxing drug ads. Claiming that Big Pharma is exploiting a loophole, Democrats and independents in the Senate and House have introduced bills that would stop companies from deducting direct-to-consumer ad spending from their tax calculations. |
By Nick Paul Taylor Sotio has struck a deal to fuse bispecifics with its antibody-drug conjugate (ADC) capabilities, agreeing to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to targeting molecules. |
By Fraiser Kansteiner As Johnson & Johson continues to attempt to Texas two-step its way around thousands of claims that its popular talcum powder-based products caused cancer, the drugmaker is putting up hundreds of millions of dollars to settle a longstanding dispute with a clutch of suppliers. |
By Kevin Dunleavy CordenPharma will invest 900 million euros ($981 million) over the next three years to bolster its ability to manufacture GLP-1 products in Europe and the United States, the German CDMO said on Tuesday. It is the largest outlay ever for the 18-year-old company. |
By Nick Paul Taylor Eli Lilly has choreographed another part of its Olympics-focused marketing campaign, partnering with seven-time medalist Simone Biles and her mom Nellie to promote the GLP-1 diabetes drug Mounjaro. |
By Andrea Park Fresh off earning FDA approval for label expansions for its LDL cholesterol-lowering Nexletol and Nexlizet tablets, Esperion Therapeutics has launched a marketing campaign to reach that newly expanded patient group. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.” |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now. 
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
